MedTrace Logo

Viral Immunotherapy in Relapsed/Refractory Multiple Myeloma

NCT03015922 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2020-01-22

No results posted yet for this study

Summary

This study will recruit patients currently receiving either lenalidomide or pomalidomide whose disease is relapsing. This is a dose escalation study and the aim is to determine the maximum tolerated dose (MTD) of REOLYSIN® that can be given in combination with lenalidomide or pomalidomide. The study will also investigate the safety, side effects and effectiveness of this treatment combination. Pomalidomide and lenalidomide will be evaluated separately as two separate groups.

Conditions

Interventions

DRUG

Lenalidomide or Pomalidomide

Patients will received either lenalidomide or pomalidomide, depending on which drug they were receiving prior to the trial (they will receive the same as before).

BIOLOGICAL

REOLYSIN

Patients will receive Reolysin alongside either lenalidomide or pomalidomide

Sponsors & Collaborators

  • Myeloma UK

    collaborator OTHER

  • Oncolytics Biotech

    collaborator INDUSTRY

  • Celgene Corporation

    collaborator INDUSTRY

  • University of Leeds

    lead OTHER

Principal Investigators

  • Gordon Cook · St. James's University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-05
Primary Completion
2021-09-01
Completion
2021-10-01

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03015922 on ClinicalTrials.gov